Peptide for treating cancer
AssigneeSaint Leo University
InventorSergiy I. Borysov
Life of this patent
Estimating the term…
Abstract
A peptide is disclosed that has an amino acid sequence selected from SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27; SEQ ID NO: 28; SEQ ID NO: 29; SEQ ID NO: 30; SEQ ID NO: 31; SEQ ID NO: 32, SEQ ID NO: 33; SEQ ID NO: 34; SEQ ID NO: 35; SEQ ID NO: 36; SEQ ID NO: 37; SEQ ID NO: 38; SEQ ID NO: 39; SEQ ID NO: 40; SEQ ID NO: 41; SEQ ID NO: 42; SEQ ID NO: 43; and/or SEQ ID NO: 44. and retro-inversion peptides thereof. The peptides disclosed herein may be used to inhibit helicase activity and treat cancer, such as liver cancer, lung cancer, breast cancer, pancreatic cancer, or brain cancer.
Claims20
A peptide comprising or consisting of an amino acid sequence selected from SEQ ID NO:
- 22, SEQ ID NO:
- 23, SEQ ID NO:
- 24, SEQ ID NO:
- 25, SEQ ID NO:
- 26, SEQ ID NO:
- 27, SEQ ID NO:
- 28, SEQ ID NO:
- 29, SEQ ID NO:
- 30, SEQ ID NO:
- 31, SEQ ID NO:
- 32, SEQ ID NO:
- 33, SEQ ID NO:
- 34, SEQ ID NO:
- 35, SEQ ID NO:
- 36, SEQ ID NO:
- 37, SEQ ID NO:
- 38, SEQ ID NO:
- 39, SEQ ID NO:
- 40, SEQ ID NO:
- 41, SEQ ID NO:
- 42, SEQ ID NO:
- 43, SEQ ID NO:
- 44 or retro-inversion peptides thereof, wherein if the peptide includes an amino acid sequence flanking an N-terminus, C-terminus, or both of the selected amino acid sequence, at least one of the flanking sequences is an altered flanking sequence.
A method of inhibiting CMG helicase function comprising contacting a cell with a helicase-inhibiting amount of a peptide comprising or consisting of an amino acid sequence selected from SEQ ID NO:
- 22, SEQ ID NO:
- 23, SEQ ID NO:
- 24, SEQ ID NO:
- 25, SEQ ID NO:
- 26, SEQ ID NO:
- 27, SEQ ID NO:
- 28, SEQ ID NO:
- 29, SEQ ID NO:
- 30, SEQ ID NO:
- 31, SEQ ID NO:
- 32, SEQ ID NO:
- 33, SEQ ID NO:
- 34, SEQ ID NO:
- 35, SEQ ID NO:
- 36, SEQ ID NO:
- 37, SEQ ID NO:
- 38, SEQ ID NO:
- 39, SEQ ID NO:
- 40, SEQ ID NO:
- 41, SEQ ID NO:
- 42, SEQ ID NO:
- 43, SEQ ID NO:
- 44 or retro-inversion peptides thereof, wherein if the peptide includes an amino acid sequence flanking an N-terminus, C-terminus, or both of the selected amino acid sequence, at least one of the flanking sequences is an altered flanking sequence.
A method of treating cancer comprising administering to a subject having the cancer with a therapeutically effective amount of a peptide comprising or consisting of an amino acid sequence selected from SEQ ID NO:
- 22, SEQ ID NO:
- 23, SEQ ID NO:
- 24, SEQ ID NO:
- 25, SEQ ID NO:
- 26, SEQ ID NO:
- 27, SEQ ID NO:
- 28, SEQ ID NO:
- 29, SEQ ID NO:
- 30, SEQ ID NO:
- 31, SEQ ID NO:
- 32, SEQ ID NO:
- 33, SEQ ID NO:
- 34, SEQ ID NO:
- 35, SEQ ID NO:
- 36, SEQ ID NO:
- 37, SEQ ID NO:
- 38, SEQ ID NO:
- 39, SEQ ID NO:
- 40, SEQ ID NO:
- 41, SEQ ID NO:
- 42, SEQ ID NO:
- 43, SEQ ID NO:
- 44 or retro-inversion peptides thereof, wherein if the peptide includes an amino acid sequence flanking an N-terminus, C-terminus, or both of the selected amino acid sequence, at least one of the flanking sequences is an altered flanking sequence, and wherein the cancer is a carcinoma or sarcoma.
Dependencies are inferred from the claim text.